Interferon gamma release assays for monitoring the response to treatment for tuberculosis: A systematic review

Clifford, Vanessa; He, Yu; Zufferey, Christel; Connell, Tom; Curtis, Nigel

doi:10.1016/j.tube.2015.07.002

Cited by 58 publications

(46 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies in which the former version QFT-G was used, it was concluded that treatment of active TB disease resulted in reduced IFN-γ release in response to the M. tuberculosis antigens [10]. Despite a decline in IFN-γ release in IGRAs by TB treatment, some literature indicated that the conversion ratio was heterogeneous, supposedly due to different genetic characteristics and the immune competence in the host who carried TB [10].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Quantiferon®-TB Gold In-Tube Assay Detects Interferon- Release Responses to Mycobacterium Tuberculosis Antigens for Extended Periods of Time

Hirama¹,

Minezaki²,

Kanazawa³

et al. 2016

Mycobact Dis

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Despite a decline in IFN-γ release in IGRAs by TB treatment, some literature indicated that the conversion ratio was heterogeneous, supposedly due to different genetic characteristics and the immune competence in the host who carried TB [10]. To minimize genetic influence, only studies conducted in Japan were compared with our data.…”

Section: Discussionmentioning

confidence: 99%

The Quantiferon®-TB Gold In-Tube Assay Detects Interferon- Release Responses to Mycobacterium Tuberculosis Antigens for Extended Periods of Time

Hirama¹,

Minezaki²,

Kanazawa³

et al. 2016

Mycobact Dis

View full text Add to dashboard Cite

“…Tuberculosis-positive patients were diagnosed using the interferon gamma release assay (IGRA) for tuberculosis (74) at Østfold Hospital Trust (SiØ) in Kalnes, Norway. Blood was collected from TB-positive volunteers after they signed a consent form approved by the Regional Committee for Medical and Health Research Ethics (REK).…”

Section: Primer Name Sequencementioning

confidence: 99%

Immunogenic Properties of Lactobacillus plantarum Producing Surface-Displayed Mycobacterium tuberculosis Antigens

Kuczkowska

Kleiveland

Minić

et al. 2017

Appl Environ Microbiol

View full text Add to dashboard Cite

Tuberculosis (TB) remains among the most deadly diseases in the world. The only available vaccine against tuberculosis is the bacille Calmette-Guérin (BCG) vaccine, which does not ensure full protection in adults. There is a global urgency for the development of an effective vaccine for preventing disease transmission, and it requires novel approaches. We are exploring the use of lactic acid bacteria (LAB) as a vector for antigen delivery to mucosal sites. Here, we demonstrate the successful expression and surface display of a Mycobacterium tuberculosis fusion antigen (comprising Ag85B and ESAT-6, referred to as AgE6) on Lactobacillus plantarum. The AgE6 fusion antigen was targeted to the bacterial surface using two different anchors, a lipoprotein anchor directing the protein to the cell membrane and a covalent cell wall anchor. AgE6-producing L. plantarum strains using each of the two anchors induced antigen-specific proliferative responses in lymphocytes purified from TB-positive donors. Similarly, both strains induced immune responses in mice after nasal or oral immunization. The impact of the anchoring strategies was reflected in dissimilarities in the immune responses generated by the two L. plantarum strains in vivo. The present study comprises an initial step toward the development of L. plantarum as a vector for M. tuberculosis antigen delivery. IMPORTANCE This work presents the development of Lactobacillus plantarum as a candidate mucosal vaccine against tuberculosis. Tuberculosis remains one of the top infectious diseases worldwide, and the only available vaccine, bacille CalmetteGuérin (BCG), fails to protect adults and adolescents. Direct antigen delivery to mucosal sites is a promising strategy in tuberculosis vaccine development, and lactic acid bacteria potentially provide easy, safe, and low-cost delivery vehicles for mucosal immunization. We have engineered L. plantarum strains to produce a Mycobacterium tuberculosis fusion antigen and to anchor this antigen to the bacterial cell wall or to the cell membrane. The recombinant strains elicited proliferative antigenspecific T-cell responses in white blood cells from tuberculosis-positive humans and induced specific immune responses after nasal and oral administrations in mice.

show abstract

“…Thus, it is probable that TSTs have higher reproducibility for serial testing in low tuberculosis incidence settings. Serial IGRA results should not be used as a biomarker to monitor response to treatment as levels remain elevated after therapy [22][23][24]. Ongoing research is focused on alternative immunodiagnostic markers of LTBI.…”

Section: Key Pointsmentioning

confidence: 99%

Diagnosis and management of latent tuberculosis

Turetz

Kevin

2016

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

Interferon gamma release assays for monitoring the response to treatment for tuberculosis: A systematic review

Cited by 58 publications

References 69 publications

The Quantiferon®-TB Gold In-Tube Assay Detects Interferon- Release Responses to Mycobacterium Tuberculosis Antigens for Extended Periods of Time

The Quantiferon®-TB Gold In-Tube Assay Detects Interferon- Release Responses to Mycobacterium Tuberculosis Antigens for Extended Periods of Time

Immunogenic Properties of Lactobacillus plantarum Producing Surface-Displayed Mycobacterium tuberculosis Antigens

Diagnosis and management of latent tuberculosis

Contact Info

Product

Resources

About